Jazz 'active and looking' at M&A deals of 'various sizes' as it wraps up Epidiolex patent fights: execs

Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought investors’ attention to the company’s appetite in dealmaking.

“We plan to further diversify our commercial and pipeline portfolios through strategic corporate development, which remains a key focus for Jazz,” Cozadd said on the call Tuesday.